New initiative aims to shorten timelines from early-stage research to late-stage clinical trials through regulatory reforms.
The U.S. Food and Drug Administration
said on Monday it is launching a series of measures to speed up
drug research, from early-stage investigational studies to
late-stage trials, under an initiative called Operation
TrialBlazer.Here are some details:* The FDA said it is planning a new pilot program that would
Federal health officials aim to speed up drug development and better compete with China.
Monitoring trials in real time may help shorten the time interval between trial phases.
Makary pointed to three bottlenecks: hospital contracting, ethical reviews and approvals and the Investigational New Drug…
HHS launches clinical trial reforms — including new pilot programs and updated FDA guidance — to accelerate US drug development…
The FDA is looking to get thrifty with its approved drugs. | The framework would leverage existing safety data on approved drugs…
An FDA draft guidance nixing the requirement for biosimilar manufacturers to conduct comparative efficacy studies may prove…
US to investigate Germany's proposed drug spending reforms
